Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

4.2%

1 terminated/withdrawn out of 24 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

4%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

10 recruiting

Enrollment Performance

Analytics

N/A
8(66.7%)
Phase 2
2(16.7%)
Phase 1
1(8.3%)
Phase 3
1(8.3%)
12Total
N/A(8)
Phase 2(2)
Phase 1(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (24)

Showing 20 of 24 trials
NCT07507578Recruiting

A Multi-omics Approach to Disclose Progression and Underlying Biology of Head and Neck Adenoid Cystic Carcinoma

Role: collaborator

NCT05766046Not ApplicableActive Not Recruiting

Lung Cancer Prevention Screening Programme in Italy

Role: collaborator

NCT07461246Active Not Recruiting

Familial Adenomatous Poliposys Italian Network (Rete Italiana Poliposi Adenomatosa Familiare)

Role: collaborator

NCT07372261Enrolling By Invitation

Validation of a Prognostic Method for Assessing the Risk of Distant Metastasis in Early-stage Breast Cancer

Role: collaborator

NCT07360964Not ApplicableActive Not Recruiting

Clear Cell Chondrosarcoma in Italy

Role: collaborator

NCT06593639Not ApplicableRecruiting

Effect of Prehabilitation on Head and Neck Cancer Patients

Role: collaborator

NCT03884543Not ApplicableCompleted

Driving Pressure During General Anesthesia for Open Abdominal Surgery

Role: collaborator

NCT04776655Phase 3Recruiting

Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB

Role: collaborator

NCT07088978Not Yet Recruiting

Adaptation of the PROFFIT Instrument Into Turkish: A Validity and Reliability Study

Role: collaborator

NCT06574373Recruiting

Identification of New Theranostic Biomarkers of Pancreatic Tumor Progression

Role: collaborator

NCT06033092Phase 2Active Not Recruiting

Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion

Role: collaborator

NCT06551909Not ApplicableRecruiting

Radioimmunotherapy in Solid Tumors (PNRR-MCNT2-2023-12378239-Aim2)

Role: collaborator

NCT05360264Phase 2Terminated

tailOred dRug repurposIng of dEcitabine in KRAS-dependeNt refracTory pAncreaTic cancEr

Role: collaborator

NCT06873685Not ApplicableRecruiting

Soft Tissue Sarcoma: Motor Performance, Robotic Rehabilitation, Nutrition, and Quality of Life

Role: collaborator

NCT06805812Recruiting

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

Role: collaborator

NCT06762977Recruiting

A Composite Assay for HER2-positive Early-stage Breast Cancer Management

Role: collaborator

NCT05947903Not Yet Recruiting

Validation of the European Oncology Quality of Life Toolkit

Role: collaborator

NCT06536179Recruiting

New Preclinical and Clinical Approaches to Mesothelioma

Role: collaborator

NCT05155618Not ApplicableUnknown

Intervention Study in Prostate Cancer Patients Undergoing Radiotherapy

Role: collaborator

NCT06080607Recruiting

PRO Survivorship Concerns ITA

Role: collaborator